Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2012

View Archived Issues

Shionogi reports milestones of second quarter of fiscal 2012

Nonviral gene therapy for heart failure presented at AHA meeting

Kancera reports preclinical data for pancreatic cancer compounds

Phase III results reported for Ruconest in acute hereditary angioedema

Senesco Technologies expands study of SNS01-T

Auxilium and Pfizer to terminate European agreement for Xiapex

Auxilium seeks approval of new indication for Xiaflex in the U.S.

Clinical benefit of GLPG-0634 in rheumatoid arthritis confirmed in phase IIa trial

FDA grants fast track status for etirinotecan pegol in metastatic breast cancer

Albireo obtains FDA orphan drug designation for A-4250 in liver diseases

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Signifor recommended by FDA advisory committee for Cushing's disease

T-3256336 proven to be a highly effective inhibitor of tumor growth in vivo

IMA-901 receives FDA orphan designation, phase III study completes enrollment

Cornerstone acquires U.S. rights to Chiesi's Bethkis for cystic fibrosis

Merck & Co. presents novel BACE inhibitors

Laboratoire Biodim discloses new agents for HIV infection

Ironwood Pharmaceuticals submits IND for antianxiety drug candidate

Sloan-Kettering Institute for Cancer Research patents new HSP 90 inhibitors

Nektar Therapeutics synthesizes promising thymidylate synthase inhibitor

FDA accepts to review NDA for suvorexant in insomnia

Scientists at Vertex Pharmaceuticals patent new protein kinase inhibitors

Merck & Co. prepares novel agents for diabetes and obesity

Pfizer divulges new lpxC inhibitors for bacterial infections

Cryopraxis and CellPraxis plan phase III trial of cell therapy for refractory angina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...